Condition 101 About Mucolipidosis Type 4

What is the definition of Mucolipidosis Type 4?

Mucolipidosis type 4 is a metabolic condition that affects the body's ability to process certain carbohydrates and fats. As a result, these materials accumulate in cells leading to the various signs and symptoms of the condition. Most people with mucolipidosis type 4 develop severe psychomotor (mental and motor skills) delay by the end of the first year of life and visual impairment that worsens over time. Other common features of the condition include limited or absent speech; intellectual disability; hypotonia that gradually progresses to spasticity; problems controlling hand movements; impaired production of stomach acids; and iron deficiency. Approximately 5% of affected people have a mild form of the condition (known as atypical mucolipidosis type 4) which is associated with milder psychomotor delay and less severe eye abnormalities. Mucolipidosis type 4 is caused by changes (mutations) in the MCOLN1 gene and is inherited in an autosomal recessive manner. Treatment is based on the signs and symptoms present in each person.

What are the alternative names for Mucolipidosis Type 4?

  • ML 4
  • Berman syndrome
  • Ganglioside neuraminidase deficiency
  • Ganglioside sialidase deficiency
  • Mucolipidosis type IV

Top Global Doctors For Mucolipidosis Type 4

Latest Advances On Mucolipidosis Type 4

There is no recent research available for this condition. Please check back because thousands of new papers are published every week and we strive to find and display the most recent relevant research as soon as it is available.

Clinical Trials For Mucolipidosis Type 4

Clinical Trial
  • Status: Active, not recruiting
  • Participants: 1000
  • Start Date: August 20, 2018
Biomarker for Glycogen Storage Diseases - AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL
Clinical Trial
  • Status: Active, not recruiting
  • Participants: 1000
  • Start Date: August 20, 2018
Biomarker for Mucolipidosis Disorder Type I, II, III, IV AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL